Annons
The new project, PD-BT2238, combines a selective alpha-synuclein oligomer targeting antibody with BioArctic’s Brain Transporter technology, to increase exposure of the antibody in the brain, with the aim of increasing efficacy of a potential treatment in Parkinson’s disease. BioArctic’s aim is to develop an antibody treatment targeting soluble aggregated forms of alpha-synuclein, a protein that […]
Sponsrat innehåll från Paroc
